Based only on the facts in our directory. The right pick still depends on the job you need done.
Lower starting price
Not comparable
Not comparable: Abridge does not list a price
Free plan
OpenEvidence
Only OpenEvidence has one
Higher rating
Abridge
4.5 against 4.4
Same job?
Yes
Both are Healthcare AI tools
Side by side
Compared on
Abridge
OpenEvidence
Our rating
4.5Better
4.4
Starts at
Not listed
Free
Free plan
No
YesBetter
Category
Healthcare AI
Healthcare AI
Plans
See pricing
Free
Key features
Ambient listening that turns patient-clinician conversations into structured notes
Deployed at Mayo Clinic, Duke Health, Johns Hopkins, and 300+ health systems
#1 Best in KLAS for Ambient AI in Revenue Cycle Management, two years running
Expanding beyond documentation into billing and clinical decision support
Roughly $830M raised, $5.3B valuation as of its Series E extension
Point-of-care clinical answers grounded in peer-reviewed literature with citations
760,000 registered US physicians, roughly 40% of all US doctors
Approximately 18 million clinical consultations handled monthly
Free for verified physicians, monetized through pharmaceutical advertising
$12B valuation after a $250M Series D in January 2026
Pros
Exceptional enterprise validation at some of the most prominent health systems
Strong, sustained KLAS recognition specifically for ambient AI quality
Expanding scope beyond documentation adds value without switching platforms
Free access for physicians removes cost as a barrier to point-of-care use
Citations grounded in peer-reviewed literature build clinical trust
Extraordinarily fast physician adoption validates genuine day-to-day utility
Cons
Enterprise pricing requires a sales conversation, no published self-serve rate
Built for large health system deployments, less suited to a solo practitioner
Broadening scope into billing and trial screening adds platform complexity to evaluate
Monetized through pharmaceutical advertising, which some clinicians may view with caution
Built for point-of-care physician use, not a full clinical documentation platform
Extremely fast valuation growth invites scrutiny over long-term sustainability
Company
Abridge, founded 2018
OpenEvidence, founded 2022
Prices come from each vendor's pricing page, last checked 20260715. Check the vendor before you buy.
FAQ
Questions people ask
Is Abridge better than OpenEvidence?
In our reviews Abridge scores 4.5 and OpenEvidence scores 4.4. The better pick depends on the job. Abridge: Deployed at 300+ health systems, now backed by a strategic investment from Eli Lilly. OpenEvidence: Used by 40% of US physicians, doubling its valuation to $12B in under a year.
OpenEvidence
Abridge
